Therefore, in the in vivo situation the bispecific Bi-FAP/HER2-IL should target the tumor cells (based on HER2 or human FAP), TAFs (based on murine FAP of host mouse) [6], and TAMs (based on phagocytosis) [33]. The gene discussed is FAP; the disease is neoplasm.